TEARCLEAR
TearClear is a pharmaceutical company that specializes in providing a class platform of drugs that enables medication delivery to ultimately enhance patient safety and compliance by capturing preservatives before they reach the ocular surface. Founded in 2015, TearClear is headquartered in California, United States.
TEARCLEAR
Social Links:
Industry:
Chemical Engineering Medical Device Pharmaceutical
Founded:
2015-12-15
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.tearclear.com
Total Employee:
1+
Status:
Active
Contact:
617-454-7251
Total Funding:
40.19 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
Moderna Therapeutics
Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Spencer Health Solutions
Spencer Health Solutions is a developer of an in-home medication dispenser.
Current Advisors List
Current Employees Featured
Founder
Investors List
Visionary Venture Fund
Visionary Venture Fund investment in Series B - TearClear
Flying L Partners
Flying L Partners investment in Series B - TearClear
Bluestem Capital
Bluestem Capital investment in Series B - TearClear
Visionary Venture Fund
Visionary Venture Fund investment in Series A - TearClear
Bluestem Capital
Bluestem Capital investment in Series A - TearClear
Key Employee Changes
| Date | New article |
|---|---|
| 2020-04-16 | TearClear Taps Former Shire Executive Robert Dempsey as CEO |
Official Site Inspections
http://www.tearclear.com
- Host name: 120.120.215.35.bc.googleusercontent.com
- IP address: 35.215.120.120
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "TearClear"
TearClear - Crunchbase Company Profile & Funding
TearClear is a pharmaceutical company that specializes in providing a class platform of drugs that enables medication delivery to ultimately enhance patient safety and compliance by capturing …See details»
TearClear
We would like to show you a description here but the site won’t allow us.See details»
TearClear - LinkedIn
TearClear is an emerging ophthalmic pharmaceutical company with the goal of disrupting the way current topical medications are delivered to the ocular surface.See details»
TearClear Company Profile 2024: Valuation, Funding & Investors
TearClear General Information Description. Developer of eye drugs intended to transform trusted ophthalmic medications into therapies. The company's drug candidates in glaucoma pave the …See details»
TearClear - Contacts, Employees, Board Members, Advisors & Alumni
Organization. TearClear . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 4. Number of Board …See details»
TearClear - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
TearClear Announces Positive Topline Results from CLEAR
Sep 29, 2022 In addition to TC-002 (latanoprost 0.005%), TearClear also filed an investigational new drug (IND) application for TC-003 (brimonidine/timolol) in June 2022, which the FDA has …See details»
TearClear - Ohio Life Sciences
TearClear is an ophthalmic pharmaceutical company transforming trusted drugs into best-in-class therapies for patients with chronic eye disease and ocular surface disease. Our lead …See details»
TearClear Raises $22 Million to Advance Multiple Clinical …
Aug 11, 2020 TearClear announces appointment of Stuart Raetzman to Board of DirectorsBOSTON, Aug. 11, 2020 (GLOBE NEWSWIRE) -- TearClear has raised $22M in a Series B funding round. The investment will be used ...See details»
TearClear Company Profile - Office Locations, Competitors ... - Craft
TearClear $31.5 m in total funding,. See insights on TearClear including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
TearClear Completes $4.5 Million Series A Financing and
May 30, 2017 TearClear Corp. is an early-stage, disruptive eye health technology company focused on developing a safe and reliable means of delivering preservative-free topical …See details»
TearClear Announces Successful Completion of Pre-IND Meeting …
Dec 1, 2020 Prepared to file an IND in mid-2021 via the 505(b)(2) NDA pathwayBOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- TearClear, an emerging ophthalmic pharmaceutical company, today announced successful ...See details»
Stuart Raetzman appointed as interim CEO at TearClear - Healio
Mar 16, 2021 TearClear has appointed Stuart Raetzman as interim CEO and is preparing for a pivotal study on proprietary latanoprost for glaucoma treatment, according to a press release.See details»
TearClear Announces Positive Topline Results from CLEAR Phase 3 …
Sep 29, 2022 TearClear Announces Positive Topline Results from CLEAR Phase 3 Study for the Treatment of Glaucoma with TC-002 (latanoprost ophthalmic solution 0.005%) TearClear …See details»
TearClear Raises $22 Million to Advance Multiple Clinical
BOSTON, Aug. 11, 2020 (GLOBE NEWSWIRE) -- TearClear has raised $22M in a Series B funding round. The investment will be used to advance multiple clinical programs in development, with two lead ...See details»
The Importance of Preservative-Free Ophthalmic Drugs
Oct 1, 2021 TearClear is an ophthalmic pharmaceutical company that transforms trusted drugs into best-in-class therapies. Our novel platform keeps preservatives safely in the bottle …See details»
TearClear - Eyetube
TearClear is an ophthalmic pharmaceutical company that transforms trusted drugs into best-in-class therapies. Our novel platform keeps preservatives safely in the bottle enabling …See details»
TearClear Moving Toward Clinical Trials and ... - Yahoo Finance
Mar 16, 2021 TearClear offers the only means of delivering a preservative-free dose directly from preserved solutions. Contact:Patrick CrowleyTearClear859-462 …See details»
TearClear Moving Toward Clinical Trials and Strengthening
Mar 16, 2021 TearClear offers the only means of delivering a preservative-free dose directly from preserved solutions. Contact: Patrick Crowley TearClear 859-462-4245See details»
TC-002 - Drug Targets, Indications, Patents - Synapse
Successfully met the primary and all secondary endpoints On track for New Drug Application (NDA) filing, with the FDA in Q1 2023 TC-002 is the first of four proprietary glaucoma drugs in …See details»